Suppr超能文献

周期性癌症筛查中提前期的贝叶斯推断。

Bayesian inference for the lead time in periodic cancer screening.

作者信息

Wu Dongfeng, Rosner Gary L, Broemeling Lyle D

机构信息

Department of Mathematics and Statistics, Mississippi State University, Mississippi State, Mississippi 39762, USA.

出版信息

Biometrics. 2007 Sep;63(3):873-80. doi: 10.1111/j.1541-0420.2006.00732.x.

Abstract

This article develops a probability distribution for the lead time in periodic cancer screening examinations. The general aim is to allow statistical inference for a screening program's lead time, the length of time the diagnosis is advanced by screening. The program's lead time is distributed as a mixture of a point mass and a piecewise continuous distribution. Simulation studies using the HIP (Health Insurance Plan for Greater New York) study's data provide estimates of different characteristics of a screening program under different screening frequencies. The components of this mixture represent two aspects of screening's benefit, namely, a reduction in the number of interval cases and the extent by which screening advanced the age of diagnosis. We present estimates of these two measures for participants in a breast cancer screening program. We also provide the mean, mode, variance, and density curve of the program's lead time. The model can provide policy makers with important information regarding the screening period, frequency, and the endpoints that may serve as surrogates for the benefit to women who take part in a periodic screening program. Though the study focuses on breast cancer screening, it is also applicable to other kinds of chronic disease.

摘要

本文针对定期癌症筛查检查中的提前期建立了一种概率分布。总体目标是对筛查计划的提前期进行统计推断,即筛查使诊断提前的时间长度。该计划的提前期分布为一个点质量和一个分段连续分布的混合。使用纽约市健康保险计划(HIP)研究数据进行的模拟研究提供了不同筛查频率下筛查计划不同特征的估计值。这种混合的组成部分代表了筛查益处的两个方面,即减少间隔期病例数以及筛查使诊断年龄提前的程度。我们给出了乳腺癌筛查计划参与者这两项指标的估计值。我们还提供了该计划提前期的均值、众数、方差和密度曲线。该模型可以为政策制定者提供有关筛查周期、频率以及可能作为参与定期筛查计划女性受益替代指标的终点的重要信息。尽管该研究聚焦于乳腺癌筛查,但它也适用于其他类型的慢性病。

相似文献

1
Bayesian inference for the lead time in periodic cancer screening.
Biometrics. 2007 Sep;63(3):873-80. doi: 10.1111/j.1541-0420.2006.00732.x.
2
A projection of benefits due to fecal occult blood test for colorectal cancer.
Cancer Epidemiol. 2009 Oct;33(3-4):212-5. doi: 10.1016/j.canep.2009.08.001. Epub 2009 Sep 4.
3
MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.
Biometrics. 2005 Dec;61(4):1056-63. doi: 10.1111/j.1541-0420.2005.00361.x.
5
Sojourn time and lead time projection in lung cancer screening.
Lung Cancer. 2011 Jun;72(3):322-6. doi: 10.1016/j.lungcan.2010.10.010. Epub 2010 Nov 13.

引用本文的文献

2
Evaluation of the Slovenian Breast Cancer Screening Programme: Years of Life Gained and Avoided Deaths.
Cancers (Basel). 2025 Feb 22;17(5):742. doi: 10.3390/cancers17050742.
3
When to initiate cancer screening exam?
Stat Interface. 2022;15(4):503-514. doi: 10.4310/21-sii716. Epub 2022 Mar 4.
4
Estimation of Lead Time via Low-Dose CT in the National Lung Screening Trial.
J Healthc Inform Res. 2018 Jun 12;2(4):353-366. doi: 10.1007/s41666-018-0027-8. eCollection 2018 Dec.
6
Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
World J Gastroenterol. 2015 Jan 7;21(1):246-53. doi: 10.3748/wjg.v21.i1.246.
7
Inferences for the Lead Time in Breast Cancer Screening Trials under a Stable Disease Model.
Cancers (Basel). 2011 Apr 26;3(2):2131-40. doi: 10.3390/cancers3022131.
8
Bayesian lead time estimation for the Johns Hopkins Lung Project data.
J Epidemiol Glob Health. 2013 Sep;3(3):157-63. doi: 10.1016/j.jegh.2013.05.001. Epub 2013 Jun 14.
9
How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening.
Med Decis Making. 2011 Jul-Aug;31(4):550-8. doi: 10.1177/0272989X10396717. Epub 2011 Mar 15.
10
Sojourn time and lead time projection in lung cancer screening.
Lung Cancer. 2011 Jun;72(3):322-6. doi: 10.1016/j.lungcan.2010.10.010. Epub 2010 Nov 13.

本文引用的文献

1
2
MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.
Biometrics. 2005 Dec;61(4):1056-63. doi: 10.1111/j.1541-0420.2005.00361.x.
3
Effect of screening and adjuvant therapy on mortality from breast cancer.
N Engl J Med. 2005 Oct 27;353(17):1784-92. doi: 10.1056/NEJMoa050518.
6
Estimation of post-lead-time survival under dependence between lead-time and post-lead-time survival.
Stat Med. 1999 Jan 30;18(2):155-62. doi: 10.1002/(sici)1097-0258(19990130)18:2<155::aid-sim12>3.0.co;2-d.
10
Estimation of the duration of a pre-clinical disease state using screening data.
Am J Epidemiol. 1983 Dec;118(6):865-86. doi: 10.1093/oxfordjournals.aje.a113705.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验